Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,685 stopped studies mapped to Malignant Thoracic Neoplasm and descendants · 90% state a reason
Over the 1,685 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01115803 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | Phase 1 | terminated | May 4, 2010 | Eli Lilly and Company | Primary objective has been met; safety and pharmacokinetics have been characterized. | Safety / toxicity |
| NCT01207726 | Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer… | Phase 2 | terminated | Sep 23, 2010 | National Cancer Institute (NCI) | Slow Accrual due to patients not wanting daily clinic administration of 5AZA and/or 6 months of… | Enrollment / accrual |
| NCT02891733 | Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung…(NTS) | — | withdrawn | Sep 7, 2016 | Fondation Hôpital Saint-Joseph | The principal investigator decided to stop the study. | Investigator |
| NCT00424840 | Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy | Phase 1 | terminated | Jan 22, 2007 | University of Massachusetts, Worcester | Poor accrual | Enrollment / accrual |
| NCT00769600 | Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated… | Phase 2 | terminated | Oct 9, 2008 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Low accrual. | Enrollment / accrual |
| NCT02162537 | Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With…(METAL2) | Phase 3 | terminated | Jun 12, 2014 | Centre Hospitalier Intercommunal Creteil | Slow inclusions due in part to a change in practices. The first chemotherapy become a standard for… | Other (stated, no rule matched) |
| NCT02258607 | Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic… | Phase 1 | terminated | Oct 7, 2014 | Sierra Oncology LLC - a GSK company | not stated | Not stated |
| NCT03346304 | Photodynamic Therapy for the Prevention of Lung Cancer(PEARL) | Phase 2 / Phase 3 | withdrawn | Nov 17, 2017 | University College, London | drug no longer available | Other (stated, no rule matched) |
| NCT01415739 | Study of Proteins in Tumor Samples From Patients With Non-Small Cell Lung Cancer | — | withdrawn | Aug 12, 2011 | Alliance for Clinical Trials in Oncology | Trial closure due to NCI NCTN transition | Other (stated, no rule matched) |
| NCT00547443 | Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in… | Phase 1 / Phase 2 | withdrawn | Oct 22, 2007 | University of Texas Southwestern Medical Center | Withdrawn as the sponsor has stopped the drug for NSCLC population | Other (stated, no rule matched) |
| NCT01891669 | A Study Of PF-06263507 In Patients With Advanced Solid Tumors | Phase 1 | terminated | Jul 3, 2013 | Pfizer | The study was terminated on June 23, 2015 due to the company's change in prioritization for the… | Safety / toxicity |
| NCT01722292 | A Study of LY2940680 in Small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Nov 6, 2012 | Eli Lilly and Company | Change in clinical strategy. | Sponsor / business decision |
| NCT03334487 | Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment… | Phase 3 | withdrawn | Nov 7, 2017 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT02353741 | Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line…(CERTAIN) | Phase 2 | terminated | Feb 3, 2015 | Xinqiao Hospital of Chongqing | too slow of recruitmentc | Enrollment / accrual |
| NCT02640326 | McMaster Catheterization for Thoracoscopic Surgery Study(UCATh) | N/A | withdrawn | Dec 28, 2015 | McMaster University | Research question no longer useful/feasible due to shifts in standards of care | Other (stated, no rule matched) |
| NCT01578551 | Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With… | Phase 2 | terminated | Apr 17, 2012 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Low enrollment | Enrollment / accrual |
| NCT00924209 | A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA… | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Study was terminated due to poor accrual. | Enrollment / accrual |
| NCT03366675 | AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] | Phase 2 | terminated | Dec 8, 2017 | Samsung Medical Center | Early detection of the purpose of the study. | Other (stated, no rule matched) |
| NCT03519958 | Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong | — | withdrawn | May 9, 2018 | AstraZeneca | The study direction does not longer aligns the sponsor's strategy | Sponsor / business decision |
| NCT00543335 | Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer | Phase 1 | terminated | Oct 12, 2007 | M.D. Anderson Cancer Center | Lack of Accrual. | Enrollment / accrual |
| NCT00745732 | Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | terminated | Sep 3, 2008 | M.D. Anderson Cancer Center | Sponsor withdrew support. | Other (stated, no rule matched) |
| NCT01446874 | Prevention of Post-operative Pneumonia (POPP)(POPP) | Phase 2 / Phase 3 | terminated | Oct 5, 2011 | Washington University School of Medicine | Slow patient accrual and plans to perform multi-center study | Enrollment / accrual |
| NCT02218242 | Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound | N/A | terminated | Aug 18, 2014 | Joel Thompson, PhD | Unable to enroll enough participants | Enrollment / accrual |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | Phase 2 | terminated | Feb 1, 2016 | Washington University School of Medicine | Low accrual, funding withdrawn by AstraZeneca, and change in clinical practice | Enrollment / accrual |
| NCT02737709 | Paclitaxel Detection in NSCLC Treated With TC Regimen | Phase 2 | terminated | Apr 14, 2016 | Sun Yat-sen University | The study have difficulty in recruiting subjectes | Enrollment / accrual |
| NCT00702962 | Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive… | Phase 1 / Phase 2 | terminated | Jun 20, 2008 | Milton S. Hershey Medical Center | Poor accrual | Enrollment / accrual |
| NCT02623595 | A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in… | Phase 2 | withdrawn | Dec 7, 2015 | Wuhan University | Patient enrollment was hard mainly due to we need at least three lesions suitable for SBRT | Enrollment / accrual |
| NCT00735878 | Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With… | Phase 1 / Phase 2 | terminated | Aug 15, 2008 | Konstantin Dragnev | data from a similar did not show efficacy. | Efficacy / futility |
| NCT00424138 | FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy(ACRIN6678) | N/A | terminated | Jan 18, 2007 | American College of Radiology Imaging Network | Recruitment obstacles; data to be combined with other resources for analysis | Enrollment / accrual |
| NCT02763761 | An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus… | Phase 2 | withdrawn | May 5, 2016 | Bristol-Myers Squibb | Insufficient enrollment | Enrollment / accrual |
| NCT02500914 | SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma | Phase 1 | terminated | Jul 17, 2015 | Stemcentrx | Strategic Considerations | Sponsor / business decision |
| NCT02580708 | Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib… | Phase 1 / Phase 2 | terminated | Oct 20, 2015 | Clovis Oncology, Inc. | Discontinued development of rociletinib in NSCLC. Stopped enrollment of new patients into all… | Enrollment / accrual |
| NCT02688907 | Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer… | Phase 2 | terminated | Feb 23, 2016 | Samsung Medical Center | change regimen | Other (stated, no rule matched) |
| NCT03106155 | Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring…([SUKSES-D]) | Phase 2 | terminated | Apr 10, 2017 | Samsung Medical Center | Decision of IP support organization | Other (stated, no rule matched) |
| NCT00260598 | LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer | Phase 2 | terminated | Dec 1, 2005 | University of Pittsburgh | LIFE Bronchoscopy equipment no longer functioning and cannot be repaired. | Other (stated, no rule matched) |
| NCT00352950 | Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer | Phase 1 | withdrawn | Jul 17, 2006 | Amgen | not stated | Not stated |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer,… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,… | Phase 1 | terminated | Jan 8, 2016 | Mayo Clinic | permanently closed per sponsor's request | Other (stated, no rule matched) |
| NCT02055170 | Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer | Phase 2 | terminated | Feb 5, 2014 | CancerCare Manitoba | Unable to improve on poor accrual to study. | Enrollment / accrual |
| NCT01058759 | Taxotere-Enoxaparin-(ENOXA)-Study | Phase 3 | terminated | Jan 29, 2010 | Hannover Medical School | The external funding (pharmaceutical company) was stopped and could not be substituded by internal… | Funding |
| NCT02672358 | Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese… | Phase 2 | withdrawn | Feb 3, 2016 | Novartis Pharmaceuticals | Company Decision | Sponsor / business decision |
| NCT02694380 | Measuring the Effect of Radiation Therapy on Patient Activity Levels | — | terminated | Feb 29, 2016 | University of Pittsburgh | Low accrual | Enrollment / accrual |
| NCT00748163 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line… | Phase 2 | withdrawn | Sep 8, 2008 | Masonic Cancer Center, University of Minnesota | Study has been abandoned for lack of available funding. | Funding |
| NCT00200382 | Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung… | Phase 2 | terminated | Sep 20, 2005 | Rasim Gucalp | The study did not achieve the statistical success to continue. | Other (stated, no rule matched) |
| NCT01028612 | Thermal Ablation Combined With External Beam Radiation Therapy for Patients With…(NSCLC) | N/A | terminated | Dec 9, 2009 | Wake Forest University Health Sciences | Slow accrual | Enrollment / accrual |
| NCT03370159 | CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung… | Phase 1 / Phase 2 | withdrawn | Dec 12, 2017 | Wake Forest University Health Sciences | Sponsor decided not to move forward | Sponsor / business decision |
| NCT01935947 | Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced… | Phase 2 | terminated | Sep 5, 2013 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00953459 | Sunitinib Malate in Treating Patients With Small Cell Lung Cancer | Phase 2 | terminated | Aug 6, 2009 | European Organisation for Research and Treatment of Cancer - EORTC | poorly recruiting | Enrollment / accrual |
| NCT03240393 | Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced… | Phase 2 | withdrawn | Aug 7, 2017 | Novartis Pharmaceuticals | Company Decision | Sponsor / business decision |
| NCT01041781 | Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without… | Phase 3 | terminated | Jan 1, 2010 | Alliance for Clinical Trials in Oncology | DSMB recommendation | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Feb 5, 2019source: clinicaltrials